Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on enGene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into enGene Therapeutics's regulatory disclosures and financial reporting.
enGene Therapeutics Inc. (ENGN) reported larger losses as it advances its lead gene-therapy candidate detalimogene in a pivotal Phase 2 LEGEND trial for bladder cancer. For the nine months ended July 31, 2026, net loss was $92.5 million with operating cash outflows of $78.3 million, and accumulated deficit reached $464.5 million.
Cash, cash equivalents and short-term marketable securities totaled about $266.3 million, and the company states this is expected to fund operating expenses and debt obligations for at least the next 12 months, helped by a November 2025 equity and pre-funded warrant raise and a new $125 million term loan facility of which $25 million is drawn. In June 2026, enGene approved a strategic restructuring that reduces its workforce by roughly 50% to conserve cash while focusing on completing LEGEND Cohort 1, adding a surfactant cohort, preparing a planned BLA submission in Q4 2026, and pre-commercial activities for a potential 2027 launch, if detalimogene is approved.
enGene Therapeutics Inc. (ENGN) reported third quarter 2026 results and clinical updates centered on its investigational non-viral gene therapy detalimogene for high-risk non-muscle invasive bladder cancer. As of July 31, 2026, the company held $266.3 million in cash, cash equivalents and marketable securities, up from $202.3 million as of October 31, 2025.
For the quarter ended July 31, 2026, total operating expenses were $34.0 million versus $29.9 million a year earlier, with research and development at $20.1 million (down from $22.6 million) and general and administrative at $13.9 million (up from $7.4 million, largely from workforce reduction-related and personnel costs). Net loss attributable to common shareholders was $32.5 million, or $0.47 per share, compared with $29.0 million, or $0.57 per share, in the prior-year period.
enGene highlighted prior interim data from LEGEND’s pivotal Cohort 1, where detalimogene without surfactant showed a 54% complete response rate at any time and a 3.2% progression rate to muscle-invasive disease, and plans a data update and a pre-BLA meeting with the FDA in 4Q 2026 with initiation of a BLA filing also planned for 4Q 2026. The company is also advancing a surfactant-plus-detalimogene cohort supported by preclinical data showing over nine-fold increases in bladder IL-12 expression, and detalimogene holds RMAT and Fast Track designations as well as inclusion in the FDA’s CMC Development and Readiness Pilot program.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of enGene Holdings Inc. common shares. Based on 66,989,466 Common Shares outstanding as of June 9, 2026, each Reporting Person is deemed to beneficially own 6,899,803 Common Shares, or 9.99% of the class. The Master Fund directly holds 4,822,169 Common Shares and 2,735,295 Pre-Funded Warrants exercisable at $0.0001 per share, but a 9.99% Beneficial Ownership Limitation currently allows exercise for only 2,077,634 Common Shares; the remaining warrants are treated as not exercisable for reporting purposes. Voting and dispositive power over these securities is shared among the Reporting Persons.
enGene Holdings Inc. received an amended Schedule 13G/A (Amendment No. 4) from a group of Venrock-affiliated investment entities and two individuals, reporting their current ownership of the company’s Common Shares. As of June 30, 2026, each reporting person discloses beneficial ownership of 0 Common Shares, representing 0.0% of the outstanding class, with no sole or shared voting or dispositive power. The group confirms that it now holds 5 percent or less of this class of securities, effectively indicating that these prior significant holders no longer maintain a reportable equity position in enGene.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report that they no longer beneficially own any common shares of enGene Therapeutics Inc. as of June 30, 2026. The filing shows 0 shares beneficially owned, representing 0.0% of the company’s common shares.
Each reporting person has no sole or shared voting or dispositive power over enGene’s common shares. The ownership percentages are calculated using 66,989,466 common shares outstanding as of June 9, 2026, as disclosed in enGene’s quarterly report.
enGene Therapeutics Inc. (ENGN) reports updated institutional ownership in this Schedule 13G/A amendment. As of June 30, 2026, Invus Public Equities directly held 5,481,984 common shares and Avicenna Life Sci Master Fund LP held 774,678 common shares. Based on 66,989,466 shares outstanding as of June 9, 2026, these positions correspond to 8.2% and 1.2% of the common shares, respectively.
Through a chain of control entities, Invus Public Equities Advisors, Invus Global Management, Siren, Avicenna GP and Ulys may each be deemed to beneficially own these holdings. Individually, Raymond Debbane may be deemed to beneficially own 6,256,662 shares, representing 9.3% of the class. The reporting persons certify that the securities are not held for the purpose of changing or influencing control of enGene, other than activities solely in connection with a nomination under Rule 14a-11.
enGene Therapeutics Inc. received an updated Schedule 13G/A from Blue Owl Capital Holdings LP reporting a small, warrant-based position in its common shares. Blue Owl reports sole voting and dispositive power over 511,177 Common Shares, all issuable upon exercise of warrants, each to acquire one Common Share.
This position represents 0.76% of enGene’s Common Shares, calculated using 66,989,466 Common Shares outstanding as of June 9, 2026 and adding the shares underlying the warrants. Blue Owl characterizes its holdings as ownership of 5 percent or less of the class and, under Rule 13d-4, states that this filing should not be deemed an admission that it is the beneficial owner of the reported securities for purposes of Sections 13(d) or 13(g) or for any other purpose.
enGene Therapeutics Inc. reported that it hosted a virtual key opinion leader event focused on emerging market research for non-muscle invasive bladder cancer (NMIBC) and its lead program, detalimogene voraplasmid. Management’s presentation describes detalimogene as a non-viral gene therapy being studied in multiple Phase 2 LEGEND cohorts for high-risk NMIBC, including BCG-unresponsive and BCG-naïve settings, with a cited 54% complete response rate at any time based on interim data as of April 21, 2026 and a tolerability profile the company characterizes as favorable.
The company states it has $285 million in cash and is targeting pivotal cohort 12‑month data and a potential BLA filing for detalimogene in the second half of 2026. Cited market research estimates an addressable U.S. NMIBC BCG-unresponsive population of about 20,000 patients, with most treated in community practices and many cycling through multiple lines of therapy. The slides also highlight benchmark U.S. NMIBC therapy pricing, with annual wholesale acquisition cost moving from $220,000 to about $690,000 per year, and discuss practice economics such as reliance on buy‑and‑bill reimbursement.
enGene Therapeutics Inc. reports that Interim Chief Business Officer Chinoporos Constantine holds a stock option covering 75,000 common shares. The option has an exercise price of $1.7500 per share, expires on 2036-06-16, and vests monthly in substantially equal amounts over 48 months commencing June 16, 2026, subject to continued service.
Kathleen P. Richton, SVP, Finance and Treasurer of enGene Therapeutics Inc., reports initial beneficial ownership of equity awards. Her holdings include 6,900 unvested RSUs granted January 30, 2026, vesting annually over four years from January 15, 2027, plus stock options for 45,000, 13,900 and 105,000 common shares at exercise prices of $7.39, $9.53 and $1.75, expiring between 2035 and 2036, all vesting over multi‑year schedules subject to continued service.